Mandated step therapy for dupilumab delays the inevitable

Brian Florenzoa University of Virginia School of Medicine, Charlottesville, VA, USA

Catherine E. Lyonsa University of Virginia School of Medicine, Charlottesville, VA, USACorrespondence[email protected]

Aaron D. Smitha University of Virginia School of Medicine, Charlottesville, VA, USA

Courtney Remingtonb Department of Dermatology, University of Virginia Medical Center, Charlottesville, VA, USA

R. Hal. Flowersb Department of Dermatology, University of Virginia Medical Center, Charlottesville, VA, USA

Bridget Bryerb Department of Dermatology, University of Virginia Medical Center, Charlottesville, VA, USA

References

Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6):1–2. doi: 10.1111/all.13401.
Web of Science ®Google Scholar
Drucker AM, Ellis AG, Bohdanowicz M, et al. Systemic immunomodulatory treatments for patients with atopic dermatitis: a systematic review and network meta-analysis. JAMA Dermatol. 2020;156(6):659–667. doi: 10.1001/jamadermatol.2020.0796.
PubMed Web of Science ®Google Scholar
Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327–349. doi: 10.1016/j.jaad.2014.03.030.
PubMed Web of Science ®Google Scholar
Boguniewicz M, Fonacier L, Guttman-Yassky E, et al. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(1):10–22.e2. doi: 10.1016/j.anai.2017.10.039.
PubMed Web of Science ®Google Scholar
Chambers J, Jenkins N. US Commercial Payer Coverage of Dupilumab Varies Widely. Center for the Evaluation of Value and Risk in Health. Published September 24, 2021. [cited 2022 December 9]. https://cevr.tuftsmedicalcenter.org/news/2021/dupilumab.
Google Scholar
Sedghi T, Gronbeck C, Aiudi DA, et al. Assessing the ethics of prior authorization denials and step therapy policies in dermatology. J Am Acad Dermatol. 2023; Published online February 22. doi: 10.1016/j.jaad.2023.02.018.
PubMedGoogle Scholar

Mandated step therapy for dupilumab delays the inevitable

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Mandated step therapy for dupilumab delays the inevitable

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date